Empowering Ethiopia: Horizon Europe Grants €4M to Tackle Non-Communicable Diseases

By HEOR Staff Writer

August 17, 2023

The ENABLE research consortium has been awarded a generous €4 million grant from Horizon Europe to combat non-communicable diseases (NCDs) in Ethiopia.

The ENABLE consortium, a collaboration between the Norwegian Institute of Public Health (NIPH) and the Ethiopian Public Health Institute (EPHI), will kick off its mission in 2024 for a period of 4 years.

The project aims to establish a program, using evidence-based interventions, to promote healthy eating habits, increase physical activity, and reduce exposure to pollution within urban communities in Ethiopia.

This initiative will be delivered across four Ethiopian cities: Addis Ababa, Adama, Harar, and Jimma, targeting pregnant women and their children in particular.

This is a prime example of how combining public health, healthcare access, and environmental health, supported by digital tools, can significantly improve a population’s health.

This project aligns with Ethiopia’s National NCD prevention strategy and contributes to closing the global knowledge gap for implementing evidence-based interventions.

The team is led by Dr Eleni Papadopoulou (NIPH) and Dr Masresha Tessema (EPHI) as they embark on this vital mission.

Reference url

Recent Posts

Advancing the Biosimilar Approval Framework: A Shift Towards Analytical Comparability

By HEOR Staff Writer

April 6, 2026

Below we highlight how the European Medicines Agency (EMA) is reshaping the biosimilar approval framework by prioritising advanced analytical characterisation over traditional comparative efficacy studies. A recently finalized reflection paper outlines a science-based, tailored clinical develo...
Current Challenges in Outcome Transparency Healthcare in Dutch Medical Specialist Care

By João L. Carapinha

In this update we highlight the persistent shortcomings in outcome transparency in Netherland's healthcare system. The 2026 baseline measurement report published by Zorginstituut Nederland and Patiëntenfederatie Nederland shows that national ambitions for transparency of care outcomes in medical ...
European Immunotherapy Approval for Ovarian Cancer: KEYTRUDA’s New Role in Treating PD-L1-P...

By HEOR Staff Writer

Immunotherapy ovarian cancer treatment has taken a major step forward in Europe. The European Commission has approved KEYTRUDA (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for adults with PD-L1 CPS ≥1 platinum-resistant recurrent ovarian, fallopian tube, or primary...